BRNS — Barinthus Biotherapeutics plc

Barinthus Biotherapeutics plc (BRNS) is a biotechnology company listed on NASDAQ. It is led by William J. Enright MBA, based in Zeus Building, Didcot, United Kingdom, OX11 0DF, with about 105 employees. Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Latest reported BRNS revenue for 2025-09-30 was $0. Net income was -$14.6M. BRNS currently screens at market cap $38.2M.

Use this BRNS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BRNS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BRNS SEC filings page. Lician reads the product cache first so this HTML stays unique to Barinthus Biotherapeutics plc even when a live quote feed is slow.